Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
**Background:** Endometrial cancer (EC) represents a substantial economic burden for patients in the United States. Patients with advanced or recurrent EC have a much poorer prognosis than patients with early-stage EC. Data on healthcare resource utilization (HCRU) and costs for patients with advanc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2023-11-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.88419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860353593769984 |
|---|---|
| author | Monica Kobayashi Jamie Garside Joehl Nguyen |
| author_facet | Monica Kobayashi Jamie Garside Joehl Nguyen |
| author_sort | Monica Kobayashi |
| collection | DOAJ |
| description | **Background:** Endometrial cancer (EC) represents a substantial economic burden for patients in the United States. Patients with advanced or recurrent EC have a much poorer prognosis than patients with early-stage EC. Data on healthcare resource utilization (HCRU) and costs for patients with advanced or recurrent EC specifically are lacking.
**Objectives:** To describe HCRU and costs associated with first-line (1L) therapy for commercially insured patients with advanced or recurrent EC in the United States.
**Methods:** This was a retrospective cohort study of adult patients with advanced or recurrent EC using the MarketScan® database. Treatment characteristics, HCRU, and costs were assessed from the first claim in the patient record for 1L therapy for advanced or recurrent EC (index) until initiation of a new anti-cancer therapy, disenrollment from the database, or the end of data availability. Baseline demographics were determined during the 12 months before the patient’s index date.
**Results:** A total of 7932 patients were eligible for inclusion. Overall, mean age at index was 61 years, most patients (77.3%) had received prior surgery for EC, and the most common 1L regimen was carboplatin/paclitaxel (59.1%). During the observation period, most patients had at least one healthcare visit (all-cause, 99.9%; EC-related, 82.8%), most commonly outpatient visits (all-cause, 91.4%; EC-related, 68.7%). The highest mean (SD) costs (US dollars) were for inpatient hospitalization for both all-cause and EC-related events ($8396 \[$15,130\] and $9436 \[$16,784\], respectively). Total costs were higher for patients with a diagnosis of metastasis at baseline than for those without a diagnosis of metastasis.
**Discussion:** For patients with advanced or recurrent EC in the United States, 1L therapy is associated with considerable HCRU and economic burden. They are particularly high for patients with metastatic disease.
**Conclusions:** This study highlights the need for new cost-effective treatments for patients with newly diagnosed advanced or recurrent EC. |
| format | Article |
| id | doaj-art-83fc4918c1954eb7944feae98444f086 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-83fc4918c1954eb7944feae98444f0862025-02-10T16:12:50ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362023-11-01102Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United StatesMonica KobayashiJamie GarsideJoehl Nguyen**Background:** Endometrial cancer (EC) represents a substantial economic burden for patients in the United States. Patients with advanced or recurrent EC have a much poorer prognosis than patients with early-stage EC. Data on healthcare resource utilization (HCRU) and costs for patients with advanced or recurrent EC specifically are lacking. **Objectives:** To describe HCRU and costs associated with first-line (1L) therapy for commercially insured patients with advanced or recurrent EC in the United States. **Methods:** This was a retrospective cohort study of adult patients with advanced or recurrent EC using the MarketScan® database. Treatment characteristics, HCRU, and costs were assessed from the first claim in the patient record for 1L therapy for advanced or recurrent EC (index) until initiation of a new anti-cancer therapy, disenrollment from the database, or the end of data availability. Baseline demographics were determined during the 12 months before the patient’s index date. **Results:** A total of 7932 patients were eligible for inclusion. Overall, mean age at index was 61 years, most patients (77.3%) had received prior surgery for EC, and the most common 1L regimen was carboplatin/paclitaxel (59.1%). During the observation period, most patients had at least one healthcare visit (all-cause, 99.9%; EC-related, 82.8%), most commonly outpatient visits (all-cause, 91.4%; EC-related, 68.7%). The highest mean (SD) costs (US dollars) were for inpatient hospitalization for both all-cause and EC-related events ($8396 \[$15,130\] and $9436 \[$16,784\], respectively). Total costs were higher for patients with a diagnosis of metastasis at baseline than for those without a diagnosis of metastasis. **Discussion:** For patients with advanced or recurrent EC in the United States, 1L therapy is associated with considerable HCRU and economic burden. They are particularly high for patients with metastatic disease. **Conclusions:** This study highlights the need for new cost-effective treatments for patients with newly diagnosed advanced or recurrent EC.https://doi.org/10.36469/001c.88419 |
| spellingShingle | Monica Kobayashi Jamie Garside Joehl Nguyen Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States Journal of Health Economics and Outcomes Research |
| title | Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States |
| title_full | Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States |
| title_fullStr | Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States |
| title_full_unstemmed | Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States |
| title_short | Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States |
| title_sort | healthcare resource utilization and costs among commercially insured patients with advanced or recurrent endometrial cancer initiating first line therapy in the united states |
| url | https://doi.org/10.36469/001c.88419 |
| work_keys_str_mv | AT monicakobayashi healthcareresourceutilizationandcostsamongcommerciallyinsuredpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates AT jamiegarside healthcareresourceutilizationandcostsamongcommerciallyinsuredpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates AT joehlnguyen healthcareresourceutilizationandcostsamongcommerciallyinsuredpatientswithadvancedorrecurrentendometrialcancerinitiatingfirstlinetherapyintheunitedstates |